Highlights ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			After market 05:49:21 pm
8.99 ^USD	+22.31%		8.92	-0.78%

05:06pm	Piper Sandler Adjusts Price Target on ImmunityBio to $6 From $5, Maintains Neutral Rating	MT
12:52pm	Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer	Apr. 25	CI
Upcoming Big Tech Earnings Buoy Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday	Apr. 23	MT
US FDA approves ImmunityBio's bladder cancer therapy	Apr. 22	RE
ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	Apr. 22	CI
U.S. FDA approves ImmunityBio's bladder cancer therapy	Apr. 22	RE
ImmunityBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
ImmunityBio Announces Data from A Phase 1 Pilot Study	Mar. 05	CI
ImmunityBio, Inc. Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial	Feb. 21	CI
Immunitybio, Inc. Announces Findings from Patient-Reported Outcomes of Participants in the Phase 2/3 Quilt 3.032 Study of N-803 Plus BCG	Feb. 05	CI
Top Stories at Midday: US Construction Spending Up 0.4% in November; Avangrid-PNM Resources Deal Terminated; Terreno Realty Sells California Property for $15.9 Million; ImmunityBio Secures $320 Million Investment	Jan. 02	MT
ImmunityBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
ImmunityBio, Inc. Announces First Data for Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-Tumor Activity	Nov. 07	CI
ImmunityBio Shares Rise After FDA Accepted Resubmitted Biologics License Application for N-803 Plus BCG	23-10-26	MT
ImmunityBio Says FDA Accepted Resubmitted Biologics License Application for N-803 Plus BCG	23-10-26	MT
ImmunityBio, Inc. Announces U.S. Food and Drug Administration Accepts its BLA Resubmission as Complete and Sets New PDUFA Date	23-10-26	CI
ImmunityBio Resubmits Biologics License Application for Bladder Cancer Combination Therapy	23-10-23	MT
ImmunityBio, Inc. Announces Biological License Application Resubmission for N-803 in BCG Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ	23-10-23	CI
ImmunityBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
ImmunityBio, Inc. Announces Findings from a Phase 1 Study Showing Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells	23-07-10	CI
ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Highlights

Filters